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Background: Hwangryun-haedok-tang (HRT) is traditional herbal medicine used to treat inflammatory-related
diseases in Asia. However, its effect on osteoclastogenesis and bone loss is still unknown. In this study, we
evaluated the effect of HRT and its fermented product (fHRT) on the receptor activator for the nuclear factor-κB
ligand-induced osteoclastogenesis using murine bone marrow-derived macrophages and postmenopausal bone
loss using an ovariectomy (OVX) rat model.
Methods: Tartrate resistant acid phosphatase (TRAP) staining was employed to evaluate osteoclast formation.
mRNA level of transcription factor and protein levels of signaling molecules were determined by real-time quantitative
polymerase chain reaction and Western blot analysis, respectively. Effect of HRT or fHRT on OVX-induced bone loss was
evaluated using OVX rats orally administered HRT, or fHRT with 300 mg/kg for 12 weeks. Micro-CT analysis of femora
was performed to analyze bone parameter.
Results: HRT or fHRT treatment significantly decreased TRAP activity and the number of TRAP positive multinuclear
cells on osteoclastogenesis. Interestingly, these inhibitory effects of HRT were enhanced by fermentation. Furthermore,
fHRT significantly inhibited mRNA and protein expression of nuclear factor of activated T cells cytoplasmic 1, which
leads to down-regulation of NFATc1-regulated mRNA expressions such as TRAP, the d2 isoform of vacuolar ATPase V(0)
domain, and cathepsin K. Administration of fHRT significantly inhibited the decrease of bone mineral density, and
improved bone parameter of femora more than that of HRT and vehicle in OVX rats.
Conclusions: This study demonstrated that lactic bacterial fermentation fortifies the inhibitory effect of HRT on
osteoclastogenesis and bone loss. These results suggest that fermented HRT might have the beneficial potential on
osteoporosis by inhibiting osteoclastogenesis.
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Osteoporosis is a bone disease characterized by an im-
paired bone strength and reduced bone mass that cause
skeletal fragility and increase the risk of fracture [1]. Es-
trogen deficiency underlying etiology of postmenopausal
osteoporosis increases bone turnover with relative in-
crease of osteoclastic bone resorption than osteoblastic* Correspondence: jyma@kiom.re.kr
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reproduction in any medium, provided the orbone formation. It results in an imbalance of bone remod-
eling, leading to a net loss of bone mineral density (BMD)
and disruption of bone micro-structure [2]. Estrogen re-
placement therapy (ERT) is widely used to prevent and to
treat postmenopausal osteoporosis [3]. However, due to
several adverse effects of ERT, the Women's Health Initia-
tive recommends that the benefits and risks of ERT should
be carefully weighed and non-hormonal treatment is con-
sidered as an alternative way for managing postmeno-
pausal osteoporosis [4]. There are growing interests in the
traditional medicine as alternative treatment for osteo-
porosis [5]. Traditional herbal medicine has an inhibitoryd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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deficiency-induced bone loss, which suggests the benefi-
cial potential of traditional medicine on postmenopausal
osteoporosis [6].
Osteoclasts differentiate from the monocyte/macro-
phage lineage of hematopoietic stem cells in the presence
of receptor activator for nuclear factor-κB ligand (RANKL)
and macrophage colony-stimulating factor (M-CSF) [7].
RANK/RANKL signaling plays a major role in osteo-
clastogenesis through the activation of downstream signal-
ing cascades, including mitogen-activated protein (MAP)
kinases (ERK [extracellular signal-regulated kinase], JNK
[c-Jun N-terminal kinase], and p38) and NF-κB [8].
RANKL/RANK signaling pathway consequently stimulates
key transcription factors, activation protein-1 (AP-1) and
nuclear factor of activated T cells (NFATc1) [7,8]. AP-1
positively regulates osteoclastogenesis by transcriptionally
inducing NFATc1 expression during early stage of osteo-
clastogenesis. NFATc1 is a master transcription factor that
regulates a series of osteoclastogenesis-specific genes, in-
cluding tartrate-resistant acid phosphatase (TRAP), the d2
isoform of vacuolar ATPase V(0) domain (ATP6v0d2),
and cathepsin K. NFATc1 rescues osteoclastogenesis in
cells lacking c-Fos, indicating that c-Fos is upstream of
NFATc1 [9].
Hwangryun-haedok-tang (HRT) is a traditional herbal
medicine used to treat inflammatory-related diseases, in-
cluding dermatitis, hepatitis, and gastritis. Investigation on
pharmacological effect of HRT suggests that HRT inhibits
an inflammatory response by decreasing eicosanoid and
nitric oxide production in carrageenan-injected rat model
[10]. However, there is no study that evaluates whether
HRT affects on RANKL-induced osteoclastogenesis.
Fermentation has been suggested as a traditional pro-
cess for enhancing the pharmacological effect of herbal
medicine based on the theory of the Oriental medicine
[11]. Fermentation increases the production of active
components in medicinal herbs, which beneficially influ-
ences health through health-promoting and disease
preventing effects. A body of evidence enhancing phar-
macological effect of medicinal herbs by fermentation in-
cludes an antioxidant effect of Anoectochilus formosanus
Hayata fermented by Lactobacillus acidophilus [12], an
anabolic effect of antler fermented by Cordyceps militaris
on osteoblast differentiation [13], and anti-aging effect of
Radix astragali fermented by Bacillus subtilis natto in hu-
man skin cells [14]. However, there is no investigation on
whether bacterial fermentation could change the pharma-
cological effect of traditional herbal medicine on osteo-
clastogenesis and ovariectomy (OVX)-induced bone loss.
This study investigated the inhibitory effect of HRT on
RANKL-induced osteoclastogenesis and whether the bac-
terial fermentation could affect this effect of HRT. In a
preliminary study, we found that Lactobacillus curvatusfermented HRT (fHRT) exerts an enhancement of inhibi-
tory effect compared to non-fermented HRT. Further-
more, we selected n-butanol as the organic solvent for
maximizing the inhibitory effect of fHRT on osteo-
clastogenesis. In this study, we explored the inhibitory
effect of n-butanol extract of HRT (HRT-BU) and
fHRT (fHRT-BU) on mRNA level of NFATc1, c-Fos, and
osteoclastogenesis-related genes, the activation of MAP
kinases and NF-κB to establish the underlying molecular
mechanism of fHRT-BU using mouse bone marrow-
derived macrophages (BMMs). To evaluate the therapeutic
potential of HRT and fHRT for treating postmenopausal
osteoporosis, we examined the inhibitory effect of HRT
and fHRT on OVX-induced bone loss.
Methods
Reagents
Coptis japonica Makino, Phellodendron chinense Schneider,
Gardenia jasminoides fructus, and Scutellaria baicalensis
Georgi were purchased from Dongkyung Inc. (Seoul,
Korea). General aerobic MRS medium and MRS agar were
purchased from Difco Co. (Detroit, MI, USA). Geniposide,
baicalin, palmatine, berberine, wogonoside, baicalein, and
wogonin were purchased from Tianjin Pharma Tech. Co.
(China). 1,25(OH)2D3, polybrene, puromycin, p-nitrophenyl
phosphate, and TFA were purchased from Sigma Chemi-
cal Co. (St. Louis, MO, USA). All antibodies were pur-
chased from Cell Signaling Technology (Danvers, MA,
USA) except NFATc1 (7A6) and c-Fos (H-125) antibodies
purchased from Santa-cruz Biotechnology Inc. (CA, USA).
Preparation of HRT
Coptis japonica Makino 250 g, Scutellaria baicalensis
Georgi 250 g, Phellodendron chinense Schneider 250 g,
and Gardenia jasminoides fructus 250 g were used in
this study. All voucher specimens were deposited in the
herbal bank of KM-Based Herbal Drug Research Group,
Korea Institute of Oriental Medicine (No. 2010–144, 166,
168, and 170). HRT was prepared by using a water extrac-
tion method (Gyeongseo Extractor Cosmos-600, Inchon,
Korea). The total quantity of medicinal herbs was placed
in 10 L of distilled water for 1 h, and then extracted by
heating for 3 h at 115°C. After extraction, HRT was fil-
tered out using standard testing sieves (106 μm) (Retsch,
Haan, Germany) and stored at 4°C before use (yield about
19.42%).
Fermentation of HRT
Lactobacillus curvatus KFRI-166 (Korea Food Research
Institute, Seongnam-si, Korea) was used for fermentation
of HRT. After two successive transfers of the test organ-
isms in MRS broth at 37°C for 24 h, the activated cultures
were again inoculated into broth. It was properly diluted
to obtain an initial population of 1–5 × 106 CFU/ml and
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were determined in duplicate by using the pour plate
method on MRS agar. For fermentation, 5 ml of HRT was
inoculated with 0.05 ml of the inoculums that was incu-
bated at 37°C for 48 h. HRT or fHRT was fractionated by
successive solvent extraction with n -hexane, ethylacetate,
and n-butanol. Each fraction evaporated to dryness under
vacuo was stored in desiccators at −20°C before use. The
n-butanol soluble fraction of HRT and fHRT was desig-
nated as HRT-BU (yield about 16.45%) and fHRT-BU
(yield about 17.23%), respectively.
HPLC analysis
The Waters HPLC system (Waters Co., USA) consisting
of a pump, autosampler, column oven, and diode array
UV/VIS detector. The output signal of the detector was
recorded using Empower software from Waters. Chro-
matographic separation was achieved in a Luna C18 col-
umn (4.6 mm × 250 mm, 5 μm, Phenomenex Co., USA)
at 254 nm. The mobile phase was 100% acetonitrile (A)
and water containing 0.1% trifluoroacetic acid (B) with a
step gradient elution (0–10 min, 90% B; 10–25 min, 80%
B; 25-33 min, 70% B; 33-43 min, 67% B; 43–50 min, 60%
B; and 50–60 min, 56% B) at a flow rate of 1.0 ml/min.
Each standard solution was prepared by dissolving each
marker components, geniposide (1), baicalin (2), palmatine
(3), berberine (4), wogonoside (5), baicalein (6) and
wogonin (7), with 100% methanol at the concentration of
0.2 mg/ml. Prior to analysis, the sample was filtered
through a 0.2 μm PVDF filter and 10 μL of samples was
injected for the HPLC analysis. We prepared two batches
of HRT, fHRT, HRT-BU, and fHRT-BU under the same
condition and analyzed marker components in each batch
by HPLC analysis. We successfully detected geniposide
(1, tR 17.51 min), baicalin (2, tR 36.10 min), palmatine (3,
tR 39.59 min), berberine (4, tR 39.77 min), wogonoside (5,
tR 41.19 min), baicalein (6, tR 48.44 min), and wogonin
(7, tR 58.5 min) in HRT and fHRT. In addition, we also
detected geniposide (tR 17.44 min), baicalin (tR 36.05 min),
palmatine (tR 39.95 min), berberine (tR 40.35 min), and
wogonoside (tR 41.11 min) in HRT-BU and fHRT-BU.
All the main peaks detected in batch 1 coincided with
batch 2, demonstrating a good reproducibility of HRT
composition.
Cell culture and osteoclast formation
BMMs and primary osteoblasts were prepared from bone
marrow cells (BMCs) in femur and calvarias of newborn
mice as described previously [15]. To generate osteoclasts,
BMMs (1 × 104 cells/well in a 96-well plate) were cultured
with M-CSF (60 ng/ml) and RANKL (150 ng/ml) for
4 days. BMCs (1 × 104 cells/well) and primary osteoblasts
(1 × 105 cells/well) were cocultured for 6 days with 1,25
(OH)2D3 (1 × 10
-8 M). A CCK-8 was used to examine cellviability according to the manufacturer’s protocol. Cells
were fixed and stained for TRAP assay. Total TRAP activi-
ty was measured at 410 nm after treatment with p-
nitrophenyl phosphate. TRAP positive multinuclear cells
(TRAP(+)MNCs) containing more than three nuclei and
larger than 100 μm in diameter were counted. Data repre-
sented the mean ± SD of triplicate.
Real-time quantitative PCR (QPCR)
To evaluate NF-κB- or NFATc1-regulated gene expres-
sion, cells (3 × 105 cells/well in a 6-well plate) were pre-
incubated with sample and M-CSF (60 ng/ml) for 2 h,
and then stimulated with RANKL (150 ng/ml) for indi-
cated times. Total RNA was isolated with an RNA-spin
total RNA Extraction Kit according to the manufac-
turer’s protocol. cDNA was synthesized from 1 μg of
total RNA in AccuPower RT-PreMix according to the
manufacturer’s protocol. SYBR green-based QPCR amp-
lification was performed using cDNA diluted to 1:3, 10
pmol of primers, and AccuPower GreenStar qPCR Mas-
ter Mix in the Applied Biosystems 7500 Real-Time PCR
System (Foster City, CA, USA). All reactions were run
in triplicate, and data were analyzed using the 2-ΔΔCT
method. HPRT was used as the internal standard.
Western blot analysis
BMMs were collected and lysed in RIPA buffer with
protease-inhibitor and phosphatase-inhibitor cocktail
tablet. Cell lysates were centrifugated at 10,000 × g for
15 min at 4°C. Protein samples were subjected to 10%
polyacrylamide gel using a Mini Protean 3 Cell (Bio-Rad,
Hercules, CA, USA) and then transferred onto a PVDF
membrane. The membrane was first incubated in blocking
buffer (10 mM Tris–HCl [pH 7.5], 150 mM NaCl, 0.1%
Tween 20, and 5% non-fat dry milk), and then sequentially
incubated with primary antibody (1 : 1000) and secondary
antibody (1 : 2000) for 1 h at room temperature. Immuno-
detection was performed using SuperSignal West Femto
Maximum Sensitivity Substrate. Chemiluminescent signals
were detected with a LAS-4000 Luminescent Image
Analyzer (Fuji Photo Film Co., Japan).
Retrovirus preparation and infection
A DNA fragment from a constitutively active form of
NFATc1 encoding HA-tagged Ca-NFATc1 (the XhoI/
Klenow-EcoRI fragment) was subcloned into the pMX-
puro vector (BamHI/Klenow-EcoRI) with puromycin as
the selective marker (pMX-Ca-NFATc1). Preparation of
retroviral stocks and viral infection were performed as de-
scribed previously [15]. Retroviral infected BMMs were
allowed to differentiate into osteoclasts for an additional
4–5 days in the presence of sample (10 μg/ml), M-CSF
(60 ng/ml), and RANKL (150 ng/ml).
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Sprague–Dawley female rats (10 weeks old) obtained
from Samtako Bio Inc. (Seoul, Korea) were housed at 22
± 1°C and 55 ± 10% humidity on a 12-h light/dark cycle
with free access to food and water. Animal experiments
were carried out in accordance with the National Insti-
tute of Health’s Guidelines for the Care and Use of La-
boratory Animals. The experiments were approved by
the Institutional Animal Care and Use Committee at the
Korea Institute of Oriental Medicine. The rats were ran-
domly divided into sham-operated (sham, n = 8) or sur-
gically OVX (OVX, n = 24). One week after surgery, the
OVX rats were randomly divided into three groups with
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Figure 1 The HPLC analysis of HRT and fHRT (A), HRT-BU and fHRT-BU
berberine, (5) wogonoside, (6) baicalein, (7) wogonin.with saline; (2) HRT: bilaterally OVX administered with
0.3 g/kg of HRT; (3) fHRT: bilaterally OVX administered
with 0.3 g/kg of fHRT. Oral administration of samples
once a day began 1 week and finished 3 months after
OVX surgery. Dosage for oral administration was based
on maximum dosage for daily administration of herbal
medicine in traditional herbal medicine clinic. The same
amount of saline was orally administered to the sham
and OVX groups.
Micro-CT analysis
Computed tomographic images of the femur of each rats
were acquired 3 month after OVX surgery, using the In-
Vivo Micro-CT (SkyScan 1076, SkyScan N.V., Belgium)inutes
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100 kV, 100 mA, 1770 ms. The beam-hardening errors
were corrected to improve the quality of the micro-CT
images by flat-field correction before scanning and
beam-hardening correction during reconstruction.
Three-dimensional models of the trabecular bone of
femur were reconstructed using SkyScan CT Analyzer
version 1.11 to evaluate the alteration of bone and the
structural parameters.Statistical analysis
Statistical difference in TRAP activity and mRNA levels
of genes were analyzed by Student’s t-test. Results of the
animal experiment were analyzed using one-way analysis
of variance followed by post-hoc Tukey HSD test for
multiple comparisons. A p value less than 0.05 were con-
sidered significant. The statistical analysis was performed
with Statistical Package for Social Sciences (SPSS10).C


































































































































Figure 2 Inhibitory effects of HRT-BU and fHRT-BU on osteoclast forma
incubated with M-CSF (60 ng/ml) and the indicated concentrations of HRT-BU
CCK-8 assay. (B) BMMs were incubated with M-CSF, RANKL (150 ng/ml), and t
primary osteoblasts were cocultured with the indicated concentrations of eac
for TRAP activity and the number of TRAP-positive multinuclear osteoclasts (T
RANKL-induced multinuclear osteoclasts were shown (100×). Data are mean ±Results
HPLC analysis of HRT-BU and fHRT-BU
To distinguish the difference of components between
non-fermented and fermented HRT, we characterized
the seven marker components in HRT by HPLC analysis
(Figure 1). We found that geniposide (−28%) was decreased
in fHRT compared to HRT, but baicalin (+249%) was in-
creased in fHRT-BU compared to HRT-BU.HRT-BU and fHRT-BU inhibit osteoclastogenesis in BMMs
and BMCs-osteoblast coculture
We evaluated the effect of HRT-BU and fHRT-BU on
RANKL-induced osteoclastogenesis in BMMs. HRT-BU
and fHRT-BU dose-dependently inhibited TRAP activity
without cytotoxicity (Figure 2A and B). Especially, fHRT-
BU exhibited a greater inhibitory effect on TRAP activity
and the formation of TRAP-positive multinuclear cells than




















tion in BMMs and BMCs-osteoblast coculture. (A) BMMs were
or fHRT-BU for 3 days, and then cell viability of BMMs was measured by
he indicated concentrations of each sample for 4 days. (C) BMCs and
h sample and 1,25(OH)2D3 (1 × 10
-8 M) for 6 days. The cells were stained
RAP(+)MNCs) was counted. (D) Representative microscopic pictures of
SD (n= 3). aP < 0.05, versus vehicle. bP < 0.05, versus HRT-BU.
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TRAP-positive multinuclear cells (Figure 2B and D). To
confirm the inhibitory effect of HRT-BU and fHRT-BU on
RANKL-induced osteoclastogenesis, we next examined the
effect of HRT-BU and fHRT-BU on osteoclastogenesis in
BMCs-osteoblast coculture condition. In this culture condi-
tion, fHRT-BU also showed a greater inhibitory effect than
HRT-BU (Figure 2C). Although the inhibitory effect of
HRT-BU at 3 μg/ml on MNC counting in BMM culture
was greater than that of HRT-BU in coculture, there was
no statistical significance. To emphasize the difference of
inhibitory effect between HRT-BU and fHRT-BU, weFigure 3 Inhibitory effects of fHRT-BU on RANKL-induced NFATc1 exp
RANKL (150 ng/ml), and sample (10 μg/ml) for the indicated time points. mRN
analyzed by QPCR. (B) Whole cell lysates (30 μg) was analyzed by Western blo
loading control. Data are mean ± SD (n = 3). aP < 0.05, versus vehicle with RANsubsequently used 10 μg/ml concentrations of fHRT and
HRT in the following study.
fHRT-BU inhibits RANKL-induced NFATc1 expression
c-Fos and NFATc1 are key transcription factors for
osteoclastogenesis. To determine the molecular mecha-
nism regulated by HRT-BU and fHRT-BU on RANKL-
induced osteoclastogenesis, we next explored mRNA
expression of NFATc1 and c-Fos. HRT-BU significantly
decreased mRNA levels of c-Fos about 2 folds less than
vehicle at day 1 and NFATc1 about 6 folds less than ve-
hicle at day 2, respectively (Figure 3A). Notably, fHRT-BUression in BMMs. (A) BMMs were incubated with M-CSF (60 ng/ml),
A expression of NFATc1, c-Fos, TRAP, ATPv0d2, and cathepsin K was
t analysis with antibodies specific for NFATc1 and c-Fos. β–actin used as
KL, bP < 0.05, versus HRT-BU with RANKL.
Figure 4 Inhibitory effects of fHRT-BU on RANKL-induced ERK
and JNK phosphorylation in BMMs. BMMs were pre-treated with
sample (10 μg/ml) for 2 h and then stimulated with RANKL (150 ng/ml)
for the indicated time points. Whole cell lysates (10 μg) was analyzed
by Western blot analysis with indicated antibodies. β–actin was used as
loading control.
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than vehicle and NFATc1 about 10 fold less than vehicle at
same day. We also investigated mRNA levels of NFATc1-
regulated osteoclastogenesis related genes, including
TRAP, ATP6v0d2, and cathepsin K. HRT-BU significantly
decreased mRNA levels of osteoclastogenesis related genes
about 4 fold less than vehicle at day 4. Furthermore,
fHRT-BU significantly decreased mRNA levels of osteo-
clastogenesis related genes about 13 to 40 fold less than
vehicle at day 4. To confirm these inhibitory effects of
HRT-BU and fHRT-BU on c-Fos and NFATc1 expression,
the protein expression of c-Fos and NFATc1 was de-
termined by Western blot analysis. fHRT-BU decreased
c-Fos expression, which was less than the inhibitory ef-
fect of HRT-BU on c-Fos expression (Figure 3B). How-
ever, when compared to vehicle and HRT-BU, fHRT-BU
inhibited RANKL-induced NFATc1 expression at day 2,
which is a time point that NFATc1 profoundly amplifies
itself during osteoclastogenesis.
fHRT-BU inhibits RANKL-induced MAP kinases activation
MAP kinases and NF-κB are RANKL-induced signaling
pathways at early stage of osteoclastogenesis. To examine
whether HRT-BU and fHRT-BU affect the activities of these
pathways, BMMs were treated with HRT-BU or fHRT-BU
and then were stimulated with RANKL for the indicated
periods of time. HRT-BU did not affect the RANKL-
induced activation of these signaling molecules (Figure 4).
But, fHRT-BU partially decreased ERK and JNK activation.
Ectopic expression of NFATc1 could not restores
osteoclast formation suppressed by fHRT-BU
NFATc1 is master transcription factor for osteoclasto-
genesis. Ectopic expression of NFATc1 induces efficient
osteoclastogenesis in the absence of RANKL and re-
stores osteoclastogenesis in the c-Fos knockout mouse
[9]. Because HRT-BU and fHRT-BU significantly in-
hibited NFATc1 mRNA and protein expression, we ex-
plored whether overexpression of NFATc1 is sufficient
to trigger osteoclastogenesis suppressed by fHRT-BU.
We introduced a recombinant retroviral construct encod-
ing a constitutively active form of NFATc1 (Ca-NFATc1)
into osteoclast precursor cells. We found that ectopic ex-
pression of Ca-NFATc1 could not fully reduce the
osteoclastogenesis inhibitory effect of HRT-BU and fHRT-
BU (Figure 5). This result suggests that HRT-BU and
fHRT-BU can act as an inhibitor of NFATc1 activity or its
downstream signaling.
fHRT prevents OVX-induced bone loss
We assessed the effect of HRT and fHRT on OVX-
induced decrease of BMD and bone microstructure by
micro-CT analysis. The OVX group significant decreased
in 70% of BMD compared to sham group (Figure 6A). Inaddition, the OVX group exhibited significant change of
bone parameters in BV/TV (−65%), BS/BV (+29%), Tb. Th
(−14%), Tb. Sp (+169%), and Tb. N (−60%). The adminis-
tration of fHRT (0.3 g/kg/day) to the OVX group signifi-
cantly recovered BMD (+81%), BS/BV (−34%), and Tb.Th
(19%) compared to OVX or HRT group (Figure 6A, C,
and D). Although the administration of HRT to the OVX
group slightly recovered BMD and BS/BV, there was no
statistical significance.
Discussion
In this study, we found that fHRT-BU significantly de-
creases RANKL-induced mRNA and protein expression
of NFATc1. The molecular mechanisms underlying the
inhibitory effect of fHRT on NFATc1 could be involved
in 1) the transcriptional induction of NFATc1 expres-
sion, 2) the transcriptional activity of NFATc1 auto-
amplification, or 3) the transcriptional activity of NFATc1
for its downstream signaling [8]. In this study we found
that fHRT-BU greatly inhibited RANKL-induced NFATc1
expression than vehicle or HRT-BU at day 2, which is a
time point that NFATc1 profoundly auto-amplifies
Figure 5 Inhibitory effects of fHRT-BU on osteoclast formation induced by ectopic expression of NFATc1 in BMMs. (A) BMMs were
infected with pMX-puro (control) or retrovirus encoding HA-tagged Ca-NFATc1 (constitutively active form) and selected with puromycin (2 μg/ml)
for 24 h. BMMs infected with retrovirus were incubated with M-CSF (60 ng/ml), RANKL (150 ng/ml), and sample (10 μg/ml) for 4 days. The cells
were stained for TRAP activity and the number of TRAP-positive multinuclear osteoclasts (TRAP(+)MNCs) were counted. (B) Representative
microscopic pictures of the cells (100×). Data are mean ± SD (n = 3). aP < 0.05, versus vehicle with RANKL, bP < 0.05, versus HRT-BU with RANKL.
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BU inhibits an ectopic and endogenous expression of
NFATc1-induced osteoclastogenesis, which is similar level
of fHRT inhibition on endogenous expression of NFATc1-
induced osteoclastogenesis. Therefore, it might suggest
that fHRT-BU acts as an inhibitor of NFATc1 transcrip-
tional activity for its auto-amplification. In addition, we
also found that fHRT-BU, but not HRT, partially affects
ERK and JNK activation, which regulates RANKL-induced
c-Fos expression through MEK1/2 or MKK7 pathway
[17,18]. c-Fos is a component of AP-1 inducing NFATc1
expression in cooperation with other transcription factor,
such as NF-κB [19]. We found that fHRT-BU did not
regulate NF-κB activation. Thus, it suggests that fHRT
might be involved in inhibiting MAP kinase-AP-1 pathway
to regulate the transcriptional induction of NFATc1 on
osteoclast differentiation [8,20,21].
Bacterial fermentation increases or generates the active
components that have beneficial effect on bone. Our re-
sults showed that fermentation of HRT generates the dif-
ferent flavonoid profile compared to non-fermented
HRT. 6-O-acylated isoflavone glycoside generated from
soybeans fermentation with Bacillus subtilis or 1,4-
dihydroxy-2-naphthoic acid, metabolic by-products of
Propionibacterium freudenreichii, has a preventive effect
on bone resorption or FK506-induced osteoporosis
[22,23]. Inhibition of osteoclastic bone resorption and/or
stimulation of osteoblastic bone formation maintainbone homeostasis by reducing bone turnover in bone
disease [1]. Therefore, bacterial fermentation might gen-
erate the inhibitory components on osteoclastogenesis,
which enhances the inhibitory effect of fHRT on OVX-
induced bone loss and decreased bone parameter. In
contrast to generation of the inhibitory molecules on os-
teoclasts by fermentation, fermentation also generates
the anabolic molecules [13,24]. Since some flavonoids
inhibiting osteoclastogenesis also have an anabolic activ-
ity on osteoblast differentiation, the stimulation of osteo-
blast differentiation might be other way of action
mechanism of fHRT inhibiting OVX-induced bone loss.
However, fHRT significantly inhibited osteoclastogenesis
in coculture condition using BMMs and primary osteo-
blast, or in single culture condition using BMMs or
RAW264.7 cells without osteoblasts (data not shown).
Thus, it might suggest that fHRT directly acts on the
differentiation of osteoclast precursor cells rather than
the differentiation of osteoblasts.
Bacteria fermentation not only generates the bioactive
components of flavonoid but also changes its structure.
Bacterial fermentation de-glycosylates, sulfates, or meth-
ylates flavonoids, which influences the absorption rate
and metabolism in the liver [25]. The structure change
of flavonoid by bacteria fermentation increases the ab-
sorption rate and the amounts absorbed, which might
elevate the bioactivity and bioavailability of active com-
ponents [26,27] and might contribute to the beneficial
Figure 6 Effect of fHRT on the bone parameters of OVX rats. BMD and bone parameter of femur were analyzed by micro-CT after 12 weeks
of HRT and fHRT administration in OVX rats. Graphs represented BMD (A), bone volume (BV/TV, B), bone surface (BS/BV, C), trabecular thickness
(Tb. Th, D), trabecular separation (Tb. Sp, E), and trabecular number (Tb. N, F). Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not
significant (G) Representative micro-CT images of femur of sham, OVX, HRT, and fHRT administrated groups.
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shows a change of the marker component profile com-
pared to HRT. We also found that HRT has no effect on
bone loss but fHRT significantly inhibits OVX-induced
bone loss. Therefore, these findings suggest that bacteria
fermentation might affect the structure of bioactive
components, the absorption rate, or the amounts absorbed
in body which at least contributes to the inhibitory effect
of fHRT on osteoclastogenesis or bone loss.
In this study, we found that HRT fermented by Lactoba-
cillus curvatus changes the concentration of geniposide
(−28%), berberine (+2.5%), and palmatine (+4%) when
compared to HRT. However, HRT fermented by Lactoba-
cillus casei slightly changed the concentration of these
components with inhibiting osteoclastogenesis by inhibit-
ing p38 and NF-κB p65 activation in our unpublished
study (data not shown). Thus, it might suggest that differ-
ent source of fermentation affects the pharmacological
contents of herbal medicine, which is involved in the dif-
ferent mechanism of action on herbal medicine.
Conclusions
We demonstrated that fHRT has an inhibitory activity
on RANKL-induced osteoclastogenesis by suppressing
NFATc1 expression, which might result in an improve-
ment of BMD and bone parameter in OVX rats. Our re-
sults suggest that bacteria fermentation enhances the
inhibitory effect of HRT on postmenopausal osteopor-
osis. Further studies are required to identify the active
components in fHRT.
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